Triple versus dual antiplatelet therapy in patients with acute st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Circulation

Volumn 119, Issue 25, 2009, Pages 3207-3214

  Chen, Kang Yin ^a   Rha, Seung Woon ^a   Li, Yong Jian ^a   Poddar, Kanhaiya L ^a   Jin, Zhe ^a   Minami, Yoshiyasu ^a   Wang, Lin ^a   Kim, Eung Ju ^a   Park, Chang Gyu ^a   Seo, Hong Seog ^a   Oh, Dong Joo ^a   Jeong, Myung Ho ^a   Ahn, Young Keun ^a   Hong, Taek Jong ^a   Kim, Young Jo ^a   Hur, Seung Ho ^a   Seong, In Whan ^a   Chae, Jei Keon ^a   Cho, Myeong Chan ^a   Bae, Jang Ho ^a   Choi, Dong Hoon ^a   Jang, Yang Soo ^a   Chae, In Ho ^a   Kim, Chong Jin ^a   Yoon, Jung Han ^a   Chung, Wook Sung ^a   Seung, Ki Bae ^a   Park, Seung Jung ^a   more..

^a Korea University College of Medicine   (South Korea)

Author keywords

Cilostazol; Myocardial infarction; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; ST SEGMENT ELEVATION; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG COMBINATION; ELECTROCARDIOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; REGISTER; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; TETRAZOLES; TICLOPIDINE;

EID: 67650761110     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.822791     Document Type: Article

References (26)

1. Daemen J, Serruys PW. Drug-eluting stent update 2007, part I: a survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation. 2007;116:316-328.
2. Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, Friedman M, Baim DS, Koglin J. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007; 115:2842-2847.
3. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813-818.
4. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593-1599.
5. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221-231.
6. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47:27-33.
7. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999;33:634-639.
8. Nishi T, Tabusa F, Tanaka T, Shimizu T, Nakagawa K. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors, IV: synthesis and biological activity of the metabolites of 6-[4-(1-cyclohexyl-1H-5- tetrazolyl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline (OPC-13013). Chem Pharm Bull (Tokyo). 1985;33:1140-1147.
9. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985; 35:1144-1149.
10. Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung. 1987;37:563-566.
11. Yoshitomi Y, Kojima S, Sugi T, Yano M, Matsumoto Y, Kuramochi M. Antiplatelet treatment with cilostazol after stent implantation. Heart. 1998;80:393-396.
12. Chen YD, Lu YL, Jin ZN, Yuan F, Lu SZ. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl). 2006;119:360-366.
13. Lee SW, Park SW, Hong MK, Lee CW, Kim YH, Park JH, Kang SJ, Han KH, Kim JJ, Park SJ. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol. 2005;95:859-862.
14. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J. 2007;71:1867-1872.
15. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21-26.
16. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826-2832.
17. Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J. 2007;71:1685-1690.
18. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008;51:1181-1187.
19. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49: 657-666.
20. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001; 85:92-93.
21. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93:229-237.
22. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352-356.
23. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46:1833-1837.
24. Nakamura N, Hamazaki T, Johkaji H, Minami S, Yamazaki K, Satoh A, Sawazaki S, Urakaze M, Kobayashi M, Osawa H, Yamabe H, Okomura K. Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med. 2003;2:180-184.
25. Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis. 2003;171:337-342.
26. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol. 2008;51:701-707.